A detailed history of Ifp Advisors, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ifp Advisors, Inc holds 2,067 shares of NBIX stock, worth $259,429. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,067
Previous 2,507 17.55%
Holding current value
$259,429
Previous $345,000 17.68%
% of portfolio
0.01%
Previous 0.02%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

SELL
$130.86 - $143.19 $57,578 - $63,003
-440 Reduced 17.55%
2,067 $284,000
Q1 2024

Jul 30, 2024

BUY
$130.4 - $143.74 $59,332 - $65,401
455 Added 22.17%
2,507 $345,000
Q4 2023

Jan 09, 2024

BUY
$106.07 - $132.76 $25,562 - $31,995
241 Added 13.31%
2,052 $270,000
Q3 2023

Oct 12, 2023

BUY
$94.02 - $117.1 $1,504 - $1,873
16 Added 0.89%
1,811 $203,000
Q2 2023

Aug 04, 2023

SELL
$89.53 - $104.87 $5,550 - $6,501
-62 Reduced 3.34%
1,795 $169,000
Q1 2023

Apr 18, 2023

SELL
$94.11 - $123.02 $8,375 - $10,948
-89 Reduced 4.57%
1,857 $187,000
Q4 2022

Feb 07, 2023

SELL
$106.72 - $127.06 $36,178 - $43,073
-339 Reduced 14.84%
1,946 $196,000
Q3 2022

Nov 08, 2022

BUY
$92.03 - $107.81 $52,181 - $61,128
567 Added 33.0%
2,285 $229,000
Q2 2022

Sep 06, 2022

BUY
$75.79 - $100.07 $130,207 - $171,920
1,718 New
1,718 $170,000
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $130,207 - $171,920
-1,718 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$72.45 - $94.81 $16,011 - $20,953
221 Added 14.76%
1,718 $161,000
Q1 2022

Aug 08, 2022

BUY
$72.45 - $94.81 $1,014 - $1,327
14 Added 0.94%
1,497 $140,000
Q4 2021

Jan 12, 2022

BUY
$79.65 - $106.22 $955 - $1,274
12 Added 0.82%
1,483 $128,000
Q3 2021

Oct 06, 2021

SELL
$86.18 - $99.03 $3,705 - $4,258
-43 Reduced 2.84%
1,471 $141,000
Q2 2021

Jul 13, 2021

SELL
$89.43 - $102.27 $9,926 - $11,351
-111 Reduced 6.83%
1,514 $147,000
Q1 2021

Apr 30, 2021

BUY
$87.57 - $119.4 $17,076 - $23,283
195 Added 13.64%
1,625 $158,000
Q4 2020

Jan 25, 2021

BUY
$86.91 - $108.33 $36,502 - $45,498
420 Added 41.58%
1,430 $137,000
Q3 2020

Oct 29, 2020

BUY
$96.16 - $135.15 $85,582 - $120,283
890 Added 741.67%
1,010 $96,000
Q2 2020

Aug 05, 2020

BUY
$85.09 - $130.36 $850 - $1,303
10 Added 9.09%
120 $15,000
Q1 2020

May 12, 2020

SELL
$75.11 - $113.76 $1,727 - $2,616
-23 Reduced 17.29%
110 $10,000
Q4 2019

Jan 17, 2020

SELL
$86.8 - $118.57 $6,683 - $9,129
-77 Reduced 36.67%
133 $14,000
Q3 2019

Nov 07, 2019

BUY
$83.82 - $101.5 $8,382 - $10,150
100 Added 90.91%
210 $19,000
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $14,347 - $18,946
-207 Reduced 65.3%
110 $10,000
Q4 2018

Jan 23, 2019

SELL
$68.32 - $124.36 $7,651 - $13,928
-112 Reduced 26.11%
317 $22,000
Q3 2018

Oct 25, 2018

BUY
$98.88 - $125.85 $11,074 - $14,095
112 Added 35.33%
429 $0
Q2 2018

Aug 07, 2018

BUY
$75.3 - $105.99 $8,057 - $11,340
107 Added 50.95%
317 $0
Q1 2018

Jun 03, 2019

SELL
$75.88 - $92.43 $531 - $647
-7 Reduced 3.23%
210 $16,000
Q1 2018

May 09, 2018

BUY
$75.88 - $92.43 $531 - $647
7 Added 3.33%
217 $0
Q4 2017

Jan 24, 2018

BUY
$58.53 - $77.59 $6,438 - $8,534
110 Added 110.0%
210 $0
Q2 2016

Jun 03, 2019

SELL
N/A
-10 Reduced 9.09%
100 $5,000
Q1 2016

Jun 03, 2019

BUY
N/A
110
110 $10,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.